Accessed February 14, 2021.
7 7 Food and Agriculture Organization of the United Nations. H7N9 situation update. February 3, 2021. Available at: http://www.fao.org/ag/againfo/programmes/en/empres/H7N9/situation_update.html. Accessed February 14, 2021.
8 8 World Health Organization. Analysis of recent scientific information on avian influenza A(H7N9) virus. Available at: https://www.who.int/influenza/human_animal_interface/avian_influenza/riskassessment_AH7N9_201702/en. February 10, 2017. Accessed February 14, 2021.
9 9 World Health Organization. Frequently asked questions on human infection caused by the avian influenza A(H7N9) virus. Update as of February14, 2014. Available at: https://www.who.int/influenza/human_animal_interface/faq_H7N9/en/. Accessed February 14, 2021.
10 10 Brandli O. The clinical presentation of tuberculosis. Respiration. 1998; 65:97–105.
11 11 Cohen R, Muzaffar S, Capellan J, et al. The validity of classic symptoms and chest radiographic configuration in predicting pulmonary tuberculosis. Chest. 1996; 109:420–3.
12 12 World Health Organization. Tuberculosis (TB). Available at: https://www.who.int/tb/en. Accessed February 14, 2021.
13 13 Centers for Disease Control and Prevention. Treatment regimens for latent TB infection (LTBI). Last reviewed: February 13, 2020. Available at: https://www.cdc.gov/tb/topic/treatment/ltbi.htm. Accessed February 14, 2021.
14 14 American Thoracic Society, Centers for Disease Control, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003; 52:1–77.
15 15 Targeted tuberculin skin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep. 2000(RR06); 49:1–54.
16 16 Centers for Disease Control and Prevention. Treatment for TB disease. Available at: https://www.cdc.gov/tb/topic/treatment/tbdisease.htm. Last reviewed: April 5, 2016. Accessed February 14, 2021.
17 17 Centers for Disease Control and Prevention. Extensively drug‐resistant tuberculosis – United States 1993‐2006. MMWR Morb Mortal Wkly Rep. 2007; 56(11):250–3.
18 18 Liu CL, Lu YT, Peng MJ, et al. Clinical and laboratory features of SARS vis‐à‐vis onset of fever. Chest. 2004; 126;509–17.
19 19 Chan PK, Tang JW, Hui DS. SARS: Clinical presentation, transmission, pathogenesis and treatment options. Clin Sci. 2006; 110:193–204.
20 20 Chen SY, Su CP, Ma MH, et al. Predictive model of diagnosing probable cases of SARS in febrile patients with exposure risk. Ann Emerg Med. 2004; 43:1–5.
21 21 Su CP, Chiang WC, Ma MH, et al. Validation of a novel SARS scoring system. Ann Emerg Med 2004; 43:34–42.
22 22 Wang TL, Jang TN, Huang CH, et al. Establishing a clinical decision rule of SARS at the emergency department. Ann Emerg Med. 2004; 43:17–22.
23 23 Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short‐term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289:2801–9.
24 24 Dwosh H, Hong H, Austgarden D, et al. Identification and containment of an outbreak of SARS in a community hospital. Can Med Assoc J. 2003; 168:1415–20.
25 25 He J‐F, Peng G‐W, Zheng H‐Z, et al. [An epidemiological study on the index cases of severe acute respiratory syndrome which occurred in different cities in Guangdong province]. Zhonghua Liu Xing Bing Xue Za Zhi. 2003; 347–9.
26 26 Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003; 302:276–8.
27 27 Poutanen SM, Low DE, Henry B, et al. Identification of SARS in Canada. N Engl J Med. 2003; 348:1995–2005.
28 28 World Health Organization. China’s latest SARS outbreak has been contained, but biosafety concerns remain. Update 7, 18 May 2004. Available at http://www.who.int/csr/don/2004_05_18a/en. Accessed February 14, 2021.
29 29 Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS‐CoV. Nat Commun. 2020; 11:222.
30 30 Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019; 169:104541.
31 31 Beigel JH, Romashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid‐19 – final report. N Engl J Med. 2020; 383: 1813–26.
32 32 World Health Organization. COVID‐19 vaccines. Available at https://www.who.int/emergencies/diseases/novel‐coronavirus‐2019/covid‐19‐vaccines. Accessed April 5, 2021..
33 33 Centers for Disease Control and Prevention. Interim guidance for emergency medical services (EMS) systems and 911 public safety answering points (PSAPs) for COVID‐19 in the United States. Available at: https://www.cdc.gov/coronavirus/2019‐ncov/hcp/guidance‐for‐ems.html. Accessed February 14, 2021.
34 34 Verbeek PR, Schwartz B, Burgess RJ. Should paramedics intubate patients with SARS‐like symptoms? Can Med Assoc J. 2003; 169:199–200.
35 35 Interdisciplinary Respiratory Protection Study Group. Protecting health care workers from SARS and other respiratory pathogens: A review of the infection control literature. AJIC. 2005; 33:114–21.
36 36 Chen MI, Chow AL, Earnest A, et al. Clinical and epidemiological predictors of transmission in Severe Acute Respiratory Syndrome (SARS). BMC Infect Dis. 2006; 6:151.
37 37 Centers for Disease Control and Prevention. Bioterrorism agents/diseases. Last reviewed: April 4, 2018. Available at: https://emergency.cdc.gov/agent/agentlist‐category.asp. Accessed February 14, 2021.
38 38 Inglesby TV, O’Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002. Update recommendations for management. JAMA. 2002; 287:2236–52.
39 39 Bell DM, Kozarsky PE, Stephens DS. Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis. 2002; 8:222–5.
40 40 Bower WA, Schiffer J, Atmar RL, et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep 2019; 68:1–14.
41 41 Anthrax. In: Heyman DL, ed. Control of Communicable Diseases Manual. 20th ed. Washington, DC: APHA Press, 2015.
42 42 Shadomy SV, Rosenstein NE. Anthrax. In: Wallace RB, ed. Maxcy‐Rosenau‐Last Public Health and Preventive Medicine. 15th ed. USA: McGraw‐Hill Medical, 2007. pp. 427–31.
43 43 Anthrax. In: Atkinson W, Hamborsky J, McIntyre L, Wolfe S, eds. Epidemiology and Prevention of Vaccine‐Preventable Diseases, 13th ed. Washington, DC: Public Health Foundation, 2015.
44 44 Bower WA, Hendricks K, Pillai S, Guarnizo J, Meaney‐Delman D. Clinical framework and medical countermeasure use during an anthrax mass‐casualty incident. CDC Recommendations . MMWR Recomm Rep. 2015; 64(RR‐4):1–22.
45 45 American Academy of Pediatrics. Botulism and infant botulism